GS_US_342-1139: Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infecti

Investigator: Anne Luetkemeyer, MD
Sponsor: Gilead Sciences, Inc.

Location(s): United States


This study will evaluate safety, tolerability, and efficacy of treatment with sofosbuvir (SOF) /GS-5816 fixed dose combination (FDC) for 12 weeks compared to treatment with SOF plus ribavirin (RBV) for 12 weeks in participants with chronic genotype 2 hepatitis C virus (HCV) infection.